BCA
SUPN icon

Berman Capital Advisors’s Supernus Pharmaceuticals SUPN Stock Holding History

Berman Capital Advisors’s Portfolio SUPN Stock Details SUPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		$0 Sell
14
-8
-36% -$215 ﹤0.01% 2215
2021
Q2 		$0 Buy
22
+8
+57% +$245 ﹤0.01% 2038
2021
Q1 		$0 Hold
14
– – ﹤0.01% 1901
2020
Q4 		$0 Buy
+14
New +$301 ﹤0.01% 1823

Other funds holding SUPN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
GKIM
GW&K Investment Management Boston, Massachusetts $11.3B AUM 31.98% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
ACB
Aristotle Capital Boston Boston, Massachusetts $1.61B AUM 19.82% 1-Year Est. Return

Berman Capital Advisors's SUPN Position: Q3 2021 in Review

Berman Capital Advisors reduced its Supernus Pharmaceuticals (SUPN) stake by 36% in Q3 2021, selling an estimated $215 and leaving 14 shares worth $0. The position accounts for ﹤0.01% of the portfolio, ranked #2215.

Berman Capital Advisors first reported a position in SUPN in Q4 2020 and has held it in 4 quarters since. 223 funds tracked by Wall St. Rank hold SUPN as of Q3 2021.

  • Berman Capital Advisors held 14 shares of Supernus Pharmaceuticals worth $0 as of Q3 2021.
  • Berman Capital Advisors sold 8 Supernus Pharmaceuticals shares in Q3 2021, an estimated $215.
  • Supernus Pharmaceuticals made up ﹤0.01% of Berman Capital Advisors's portfolio in Q3 2021, its #2215 holding.
  • Berman Capital Advisors first reported a position in Supernus Pharmaceuticals in Q4 2020 and has held it in 4 quarters since.
  • 223 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q3 2021.

Based on Berman Capital Advisors's 13F filing for Q3 2021, filed 7 Oct 2021.